Cargando…

The impact of comorbidities on selexipag treatment effect in patients with pulmonary arterial hypertension: insights from the GRIPHON study

AIMS: The number of pulmonary arterial hypertension (PAH) patients with comorbidities is increasing and there are limited data on response to PAH‐targeted therapies in this population. These post hoc analyses explored the effect of selexipag in PAH patients with cardiovascular comorbidities in the G...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rosenkranz, Stephan, Channick, Richard, Chin, Kelly M., Jenner, Bartosz, Gaine, Sean, Galiè, Nazzareno, Ghofrani, Hossein‐Ardeschir, Hoeper, Marius M., McLaughlin, Vallerie V., Du Roure, Camille, Rubin, Lewis J., Sitbon, Olivier, Tapson, Victor, Lang, Irene M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Ltd. 2021
Materias:	Comorbidities
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9298818/ https://www.ncbi.nlm.nih.gov/pubmed/34806261 http://dx.doi.org/10.1002/ejhf.2369

Ejemplares similares

Targeting the Prostacyclin Pathway with Selexipag in Patients with Pulmonary Arterial Hypertension Receiving Double Combination Therapy: Insights from the Randomized Controlled GRIPHON Study
por: Coghlan, J. Gerry, et al.
Publicado: (2018)

Selexipag treatment for pulmonary arterial hypertension associated with congenital heart disease after defect correction: insights from the randomised controlled GRIPHON study
por: Beghetti, Maurice, et al.
Publicado: (2019)

Long-Term Survival, Safety and Tolerability with Selexipag in Patients with Pulmonary Arterial Hypertension: Results from GRIPHON and its Open-Label Extension
por: Galiè, Nazzareno, et al.
Publicado: (2021)

Selexipag for the treatment of connective tissue disease-associated pulmonary arterial hypertension
por: Gaine, Sean, et al.
Publicado: (2017)

Association of N-Terminal Pro Brain Natriuretic Peptide and Long-Term Outcome in Patients With Pulmonary Arterial Hypertension: Insights From the Phase III GRIPHON Study
por: Chin, Kelly M., et al.
Publicado: (2019)

Early selexipag initiation and long-term outcomes: insights from randomised controlled trials in pulmonary arterial hypertension
por: Coghlan, J. Gerry, et al.
Publicado: (2023)

Future perspectives in pulmonary arterial hypertension
por: Simonneau, Gérald, et al.
Publicado: (2016)

The Impact of Frailty and Comorbidities on Heart Failure Outcomes
por: Salmon, Thomas, et al.
Publicado: (2022)

New horizons in pulmonary arterial hypertension management
por: McLaughlin, Vallerie, et al.
Publicado: (2014)

A paradigm shift in pulmonary arterial hypertension management
por: Rubin, Lewis J., et al.
Publicado: (2013)

An overview of the 6th World Symposium on Pulmonary Hypertension
por: Galiè, Nazzareno, et al.
Publicado: (2019)

Improving patient outcomes in pulmonary hypertension
por: Galiè, Nazzareno, et al.
Publicado: (2015)

New horizons in pulmonary arterial hypertension therapies
por: Galiè, Nazzareno, et al.
Publicado: (2013)

The effect of anti-TNF treatment on body composition and insulin resistance in patients with rheumatoid arthritis
por: van den Oever, I. A. M., et al.
Publicado: (2020)

Diabetes and pre‐diabetes in patients with heart failure and preserved ejection fraction
por: Jackson, Alice M., et al.
Publicado: (2022)

Urinary peptides in heart failure: a link to molecular pathophysiology
por: He, Tianlin, et al.
Publicado: (2021)

Intravenous ferric carboxymaltose in iron-deficient chronic heart failure patients with and without anaemia: a subanalysis of the FAIR-HF trial
por: Filippatos, Gerasimos, et al.
Publicado: (2013)

Cardiopulmonary factors affecting 6-min walk distance in patients with idiopathic inflammatory myopathies
por: Mugii, Naoki, et al.
Publicado: (2018)

Cardiovascular system changes in rheumatoid arthritis patients with continued low disease activity
por: Biskup, Małgorzata, et al.
Publicado: (2018)

Osteoporosis in patients with rheumatoid arthritis: trends in the German National Database 2007–2017
por: Lindner, Lisa, et al.
Publicado: (2020)

Serum CXCL13 levels are associated with lymphoma risk and lymphoma occurrence in primary Sjögren’s syndrome
por: Traianos, Emmanuella Young, et al.
Publicado: (2020)

Self-reported fatigue in patients with rheumatoid arthritis compared to patients with cancer: results from two large-scale studies
por: Müller, Karolina, et al.
Publicado: (2021)

The association between type 2 diabetes and anhedonic subtype of major depression in hypertensive individuals
por: Willame, Hadrien, et al.
Publicado: (2022)

Analysis of integrated clinical safety data of tadalafil in patients receiving concomitant antihypertensive medications
por: Kloner, Robert A., et al.
Publicado: (2022)

Tadalafil in patients on antihypertensive medications: Does safety remain an issue?
por: Theofilis, Panagiotis, et al.
Publicado: (2022)

The role of tadalafil in treated hypertensive patients with erectile dysfunction
por: Grossman, Ehud
Publicado: (2022)

The Effect of Iron Deficiency on Cardiac Function and Structure in Heart Failure with Reduced Ejection Fraction
por: Martens, Pieter
Publicado: (2022)

Hyperkalaemia in Heart Failure
por: Ismail, Umar, et al.
Publicado: (2021)

Additional burden of iron deficiency in heart failure patients beyond the cardio‐renal anaemia syndrome: findings from the BIOSTAT‐CHF study
por: Alnuwaysir, Ridha I.S., et al.
Publicado: (2021)

Cardiovascular risk and mortality in patients with hyperuricemia treated with febuxostat or allopurinol: a retrospective nation-wide cohort study in Austria 2014–2017
por: Weisshaar, Stefan, et al.
Publicado: (2022)

Evolution of tricuspid regurgitation after transcatheter edge‐to‐edge mitral valve repair for secondary mitral regurgitation and its impact on mortality
por: Adamo, Marianna, et al.
Publicado: (2022)

Use of guideline‐recommended medical therapy in patients with heart failure and chronic kidney disease: from physician's prescriptions to patient's dispensations, medication adherence and persistence
por: Janse, Roemer J., et al.
Publicado: (2022)

Dapagliflozin and atrial fibrillation in heart failure with reduced ejection fraction: insights from DAPA‐HF
por: Butt, Jawad H., et al.
Publicado: (2021)

Effects of mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction patients with chronic obstructive pulmonary disease in EMPHASIS‐HF and RALES
por: Yeoh, Su E., et al.
Publicado: (2021)

Pulmonary arterial hypertension: tailoring treatment to risk in the current era
por: Gaine, Sean, et al.
Publicado: (2017)

Using a knowledge translation program to facilitate guideline‐ and evidence‐based patient management: the PAH‐QuERI Extension Program
por: McLaughlin, Vallerie V., et al.
Publicado: (2022)

Initial combination therapy with ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH): subgroup analysis from the AMBITION trial
por: Coghlan, John Gerry, et al.
Publicado: (2017)

Incident and prevalent cohorts with pulmonary arterial hypertension: insight from SERAPHIN
por: Simonneau, Gérald, et al.
Publicado: (2015)

Association between six-minute walk distance and long-term outcomes in patients with pulmonary arterial hypertension: Data from the randomized SERAPHIN trial
por: Souza, Rogério, et al.
Publicado: (2018)

SERAPHIN haemodynamic substudy: the effect of the dual endothelin receptor antagonist macitentan on haemodynamic parameters and NT-proBNP levels and their association with disease progression in patients with pulmonary arterial hypertension
por: Galiè, Nazzareno, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_i88429fiom14iupdsdc10nbokj